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Genome-wide association study identifies variants
at 16p13 associated with survival in multiple
myeloma patients
Elad Ziv1,*, Eric Dean2,*, Donglei Hu1, Alessandro Martino3, Daniel Serie4, Karen Curtin5, Daniele Campa3,
Blake Aftab6, Paige Bracci7, Gabriele Buda8, Yi Zhao5, Jennifer Caswell-Jin1, Robert Diasio9, Charles Dumontet10,
Marek Dudzin´ski11, Laura Fejerman1, Alexandra Greenberg12,13, Scott Huntsman1, Krzysztof Jamroziak14,
Artur Jurczyszyn15, Shaji Kumar16, Djordje Atanackovic5, Martha Glenn5, Lisa A. Cannon-Albright5,
Brandt Jones5, Adam Lee9, Herlander Marques17, Thomas Martin6, Joaquin Martinez-Lopez18,
Vincent Rajkumar16, Juan Sainz19,20, Annette Juul Vangsted21, Marzena Wa˛tek22, Jeffrey Wolf6,
Susan Slager23, Nicola J. Camp5,w, Federico Canzian3,w & Celine Vachon13,w
Here we perform the first genome-wide association study (GWAS) of multiple myeloma
(MM) survival. In a meta-analysis of 306 MM patients treated at UCSF and 239 patients
treated at the Mayo clinic, we find a significant association between SNPs near the gene
FOPNL on chromosome 16p13 and survival (rs72773978; P¼6 10 10). Patients with the
minor allele are at increased risk for mortality (HR: 2.65; 95% CI: 1.94–3.58) relative to
patients homozygous for the major allele. We replicate the association in the IMMEnSE
cohort including 772 patients, and a University of Utah cohort including 318 patients
(rs72773978 P¼0.044). Using publicly available data, we find that the minor allele was
associated with increased expression of FOPNL and increased expression of FOPNL was
associated with higher expression of centrosomal genes and with shorter survival.
Polymorphisms at the FOPNL locus are associated with survival among MM patients.
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M
ultiple myeloma (MM) is an incurable haematological
malignancy of plasma cells. Approximately 22,000 new
cases are diagnosed each year in the United States and
over 10,000 deaths occur annually1. Family history is a strong risk
factor for MM2. Recent genome-wide association studies (GWAS)
reported eight loci associated with susceptibility to MM3–5.
A variety of clinical features and biomarkers are associated
with MM prognosis6. Chromosomal abnormalities are also
associated with prognosis; deletions at 17p, 13q, amplifications
at 1q and translocations t(4;14) and t(14;16) have been associated
with a poor prognosis, while hyperdiploidy is associated with a
favourable prognosis7–9. Gene expression signatures of the
myeloma cells also predict survival10–14.
Germline genetic variants are associated with survival among
patients with oesophageal15, breast16,17, pancreatic18,19 and small
cell lung cancer20. We performed the first GWAS of MM survival,
by conducting a meta-analysis of two studies from the University
of California San Francisco (UCSF) and the Mayo Clinic. We
found a locus on chromosome 16 associated with survival. We
replicated the findings in the International Multiple Myeloma
rESEarch (IMMEnSE) consortium and the University of Utah
cohort. The top single-nucleotide polymorphisms (SNPs) were at
the FOPNL locus. Using publicly available data of gene expression
from peripheral blood of normal individuals, we found that the
risk alleles at the top SNPs were associated with increased
expression of FOPNL. We also found that increased expression of
FOPNL was associated with higher ‘centrosome index’, a gene
expression correlate of centrosome amplification in MM cells,
which has been associated with poor survival.
Results
Identifying a locus for survival. We performed a GWAS of
overall survival among MM patients in cohorts (Table 1) from
UCSF (n¼ 306) and Mayo Clinic (n¼ 239) separately. One locus
mapping to chromosome 16p13.11 (Hg19) showed a suggestive
association in both the UCSF (P¼ 8.4 10–7; proportional
hazards model) and the Mayo Clinic studies (P¼ 1.1 10–4;
proportional hazards model). In a meta-analysis of these GWAS,
the locus was genome-wide significant (Fig. 1a) with the strongest
evidence at two SNPs in perfect linkage disequilibrium
rs72773978 and rs117863986 (P¼ 6.0 10–10 for both; meta-
analysis P value is calculated using inverse variance-based
weighting). We found no significant deviation from the
proportional hazards assumption for the top SNP in either the
UCSF (P¼ 0.74; P values calculated by testing whether scaled
Schoenfeld residuals vary with time) or Mayo clinic studies
(P¼ 0.95). We identified 131 SNPs at this locus associated with
survival at Po5x10–8 (Supplementary Data 1); these SNPs had
B5–7% minor allele frequency (MAF) and were in tight linkage
disequilibrium (r240.8) with the top SNPs (Fig. 1b). Of the 131
top SNPs, 17 were genotyped in the UCSF data set and 1 was
genotyped in the Mayo Clinic data set (Supplementary Data 1).
The remaining SNPs were imputed but had very high imputation
quality scores (Information 40.9 or r240.9). We directly
genotyped eight additional SNPs in the Mayo clinic data set,
including one of the top two SNPs, rs117863986, and found
consistently strong levels of association with the genotyped SNPs
(rs117863986 hazard ratio (HR): 2.26; 95% confidence interval
(CI): 1.46–3.40; P¼ 0.00021; proportional hazards model) and
other SNPs (Supplementary Table 1).
Analysis of the genome-wide distribution of association
statistics (Supplementary Fig. 1a) revealed minimal deviation
from the expectation under the null (lambda¼ 1.002). After
removing SNPs from a 200-kB region around the top locus on
chromosome 16, we found no evidence for additional signal
genome wide (Supplementary Fig. 1b), although some other loci
had some suggestive signals with P values 5 10–7–1 10–7
(Supplementary Data 1).
The UCSF study had a median time of 7.6 months
(interquartile range 5.7–8.9 months) between the date of
diagnosis and the date of ascertainment. Therefore, we considered
whether this delay affected our results. First, we adjusted for the
time difference between the date of diagnosis and ascertainment
in the proportional hazards models and found no attenuation
(Supplementary Table 2). We also considered models stratified by
the delay between date of diagnosis and ascertainment
Table 1 | Clinical characteristics of patients in discovery and replication studies.
UCSF (N¼ 306) Mayo Clinic (N¼ 239) IMMEnSE Cohorts and University of Utah (N¼ 1,090)
Age at diagnosis, mean (s.d.) 55.9±9.0 62.2±11.4 54.4±10.1
Average follow-up time, mean years (s.d.) 3.8±2.5 5.3±3.5 4.8±3.3
Mortality, N (%) 103 (33.7) 174 (72.8) 423 (38.5%)
Type of disease (N with data) 292 239 649
IgG Kappa, N (%) 127 (43.5) 86 (36.0) 145 (22.3)
IgG Lambda, N (%) 44 (15.1) 49 (20.5) 64 (9.9)
IgG light chain not specified, N (%) 11 (3.8) — 173 (26.7)
IgA Kappa, N (%) 31 (10.6) 35 (15.0) 35 (5.4)
IgA Lambda, N (%) 21 (7.2) 22 (9.1) 33 (5.1)
IgA light chain not specified, N (%) — — 75 (11.6)
Light chain only, N (%) 51 (17.5) 31 (13.0) 86 (13.3)
Other/nonsecretory, N (%) 7 (2.4) 16 (6.7) 38 (5.9)
ISS stage (N with data) 140 221 513
1, N (%) 49 (35.0) 86 (38.9) 162 (31.6)
2, N (%) 55 (39.3) 74 (33.5) 165 (32.2)
3, N (%) 36 (25.7) 61 (27.6) 186 (36.3)
Durie–Salmon stage (N with data) 256 187 633
IA or IB, N (%) 39 (15.2) 14 (7.5) 69 (10.9)
IIA or IIB, N (%) 40 (15.6) 30 (16.4) 149 (23.5)
IIIA or IIIIB, N (%) 177 (69.2) 143 (76.5) 415 (65.6)
IMMEnSE, International Multiple Myeloma rESEarch; UCSF, University of California San Francisco.
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(Supplementary Table 2). We found that the effect was consistent
among patients enrolled between 0 and 5.9 months after
diagnosis (HR: 3.23; 95% CI: 1.28–8.17; P¼ 0.013; proportional
hazards model) those enrolled between 6 and 11.9 months after
diagnosis (HR: 3.04; 95% CI: 1.67–5.55; P¼ 0.00028; proportional
hazards model) and those enrolled from 12 to 23.9 months
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Figure 1 | GWAS results for survival among MM patients. (a) Manhattan plot of results of genome-wide association analysis for survival in MM
patients. Each point represents the negative log P value of the meta-analysis for association with survival using the UCSF and Mayo Clinic data.
(b) Locuszoom plot for association statistics at the 16p13 region in the meta-analysis of UCSF and Mayo. Each dot represents the negative log P value for
the association statistics from the meta-analysis. The top associated SNP (rs72773978) is coloured in purple and the remaining SNPs are coloured
according to linkage disequilibrium values (r2) with the top SNP.
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(HR: 5.06; 95% CI: 1.18–21.79; P¼ 0.029; proportional hazards
model). Thus, we concluded that the delay between diagnosis and
ascertainment within the first 2 years was unlikely to affect the
association between the SNP and overall survival. We also
considered models that adjusted for the difference between date
of diagnosis and ascertainment in the Mayo study and found no
change in the association as expected (Supplementary Table 2),
since nearly all of the participants were ascertained within 1
month of diagnosis.
We searched for additional SNPs that were associated
independently of the top SNP by performing conditional analyses
including rs72773978 and other SNPs within 100 kB of that SNP.
We performed survival analyses for all SNPs that were either in
no lethal dose (LD; R2o0.1) or in modest LD (R2 0.1–0.5) with
RS72773978, adjusting for the effect of principal components
(PC’s) and for the effect of RS72773978. We found no other
significant associations in the locus after adjusting for multiple
hypothesis testing.
The median survival was decreased by B2.7 years among
patients who were either heterozygous or homozygous for the
rare variant (T allele) of rs72773978 compared with patients
homozygous for the common variant in both the UCSF and
Mayo Clinic cohorts (Fig. 2). In models that adjusted for age,
gender and genetic ancestry, B10–14% of patients had an
increased risk of death (hazard ratioB2.6; Table 2) in the meta-
analysis of these two data sets.
We also performed a separate analysis of individuals who
genetically clustered with Caucasians in the UCSF data set
(Supplementary Fig. 2). We repeated the meta-analysis of the
Mayo Clinic data with the UCSF Caucasian-only sample
(Supplementary Table 3), and found that the association with
rs72773978 remained significant (P¼ 2.4 10–9; proportional
hazards model). The UCSF cohort included African American
patients (N¼ 25) and patients of Latino (N¼ 27) or other
patients who clustered with those of mixed ancestry (N¼ 24).
In an analysis of these patients, we also found a nominally
significant association between shorter survival and the minor
allele (HR: 2.43; 95% CI: 1.09–5.39; P¼ 0.029 proportional
hazards model).
We also examined whether the top SNPs that we identified
were associated with susceptibility to MM in our two studies. We
found no significant difference in genotype frequencies between
cases and controls (Supplementary Table 4).
Relationship to stage at diagnosis and treatment. We evaluated
the effect of the genotype on survival after adjustment for the
clinical stage. In analyses that adjusted for stage using either
the international staging system (ISS) definition or the Durie–
Salmon staging system, the rs72773978 genotype remained a
strong predictor of survival (Table 2). Among the participants in
the Mayo Clinic on whom LDH levels were available (N¼ 154),
we saw a consistent level of association (HR: 2.25; 95% CI: 1.26–
4.03; P¼ 0.006; proportional hazards model).
Since MM treatment has improved significantly in the
last decade, we used data available from both cohorts to
determine whether the SNP effect varied by initial treatment
(Supplementary Table 5). We found a consistent effect of the SNP
regardless of the type of treatment initiated (Table 3) and no
evidence of interaction between treatment and the SNP in either
the UCSF (P¼ 0.9; P for interaction derived using proportional
hazards model) or Mayo Clinic (P¼ 0.52; P for interaction
derived using proportional hazards model) cohorts.
Among patients in the Mayo Clinic study, 134 (56%) were
treated with both high-dose chemotherapy (HDC) followed by
autologous stem cell rescue. We adjusted for HDC in the
proportional hazards models and found that, although HDC was
a strong predictor of longer survival in the cohort, there was only
mild attenuation of the SNP association with survival
(Supplementary Table 6). Since nearly all (97%) of the UCSF
patients received HDC, the same analysis could not be performed
within the UCSF study.
Replication. We replicated the association of top SNPs from the
UCSF and Mayo Clinic meta-analysis in a replication meta-
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Figure 2 | Kaplan–Meier Survivorship plot by genotype for rs72773978.
(a) UCSF (N¼ 306); (b) Mayo (N¼ 239) and (c) IMMENSE/Utah
(N¼ 1,080) studies. We plotted the results by genotype. To generate the
plots for the discovery data sets, we rounded the imputation results to the
nearest whole numbers to infer genotypes of individuals.
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analysis of 1,090 MM cases, including 772 European MM patients
from the IMMEnSE consortium and 318 from the Utah cohort
(Supplementary Table 7). We selected two SNPs for replication
including rs72773978, one of the top associated SNPs from the
meta-analysis and rs12598966, a SNP resulting in an amino-acid
substitution in the FOPNL gene. We performed a meta-analysis of
all of the replication studies and found a significant association
between rs72773978 and survival in the replication cohorts
adjusted by age and sex (HR: 1.34; 95% CI: 1.01–1.74; P¼ 0.044;
proportional hazards model) with survival shorter byB1.2 years
among carriers of the minor allele (Fig. 2c). There was no
evidence of heterogeneity of effect within the replication studies
(P¼ 0.14; w2-test for heterogeneity). The other SNP, rs12598966,
was not significantly associated with survival in the replication.
We noted a slightly stronger effect size in analyses that adjusted
for stage. However, the change in effect size was not due to
negative confounding between stage and the SNP, but rather to
the fact that the cohorts with missing data on stage were the ones
with an inconsistent point estimate (Supplementary Table 3). In a
meta-analysis that did not adjust for the ISS stage but just
included participants without missing data on the ISS stage,
we saw approximately the same effect size (HR: 1.71; 95% CI:
1.18–2.47; P¼ 0.005; proportional hazards model) as in the meta-
analysis that adjusted for the ISS stage (Supplementary Table 7).
Analysis of function. The top SNPs were in a region that
overlapped the entire FOPNL gene and a portion of the MYH11
gene (Fig. 1b). In addition, known drug transporters, ABCC1 and
ABCC6, are located B50 and 300 kb away, respectively. One of
the top SNPs, rs12598966, is located in the coding sequence of
FOPNL and leads to a nonsynonymous amino-acid substitution:
Glu-4Lys at amino acid 156; however, this SNP was not sig-
nificantly associated with survival in the replication and was not
predicted to have a deleterious effect on protein function (sorting
intolerant from tolerant (SIFT) score¼ 0.89 and Polyphen 2
score¼ 0.275). Next, we investigated the top 145 SNPs (all in
tight LD (r240.8) with rs72773978) for an effect on gene
expression using GENEVAR21. The top two SNPs, rs72773978
and rs117863986, were not included in the database; however, six
other SNPs in strong LD (r2¼ 1) with rs72773978 are present in
the database and are associated with expression of FOPNL
(Supplementary Table 8). The minor allele of these SNPs
predicted higher expression of FOPNL. There was no significant
association between these SNPs and expression of other genes
within 1MB of the locus.
We identified 13 SNPs in LD with rs72773978 as being
potentially functional (Supplementary Table 9). Six of these SNPs
are in the 30 untranslated repeat of the FOPNL gene and,
therefore, may be involved in transcript stability. Seven SNPs
were identified as being in sites of open chromatin and thus may
be involved in transcriptional regulation.
Since the top SNPs were associated with gene expression, we
hypothesized that expression of FOPNL may be associated with
survival among MM patients. In particular, higher expression of
FOPNL is associated with the minor allele of the top SNPs from
the GWAS and should also be associated with shorter survival.
We used publicly available data on gene expression (GSE2658)
and survival from 414 MM cases to test this hypothesis13. As
predicted, we found a significant association between higher
expression of FOPNL and worse survival (Supplementary
Table 10). FOPNL is known to localize to the centrosome and
the pericentriolar satellites. Since centrosome amplification is
known to be a predictor of poor prognosis, we evaluated the
association between FOPNL expression and the centrosome
index, a previously validated gene expression signature of
centrosome amplification. We found a very strong correlation
(Supplementary Table 11) between higher FOPNL expression and
increased centrosome index in the study we analysed for survival
(GSE2658) and in two additional studies (GSE19784 and
GSE26760).
Discussion
We performed a GWAS for survival among MM patients and
identified SNPs at chromosome 16p13 that were strongly
Table 2 | Association of rs72773978 and MM survival.
Study Allele
frequency
HR 95% CI P value*
Age- and sex-adjustedw
UCSF (n¼ 306) 0.075 3.03 1.95–4.73 8.0 10–7
Mayo (n¼ 239) 0.054 2.31 1.51–3.53 1.1 10–4
Discovery meta-analysis
(UCSF and Mayo)
2.65 1.94–3.58 6.0 10–10
Replicationz (1,090):
IMMEnSE n¼ 772, Utah
n¼ 315
0.051 1.34 1.01–1.78 0.044
Discovery and replication
meta-analysis
1.93 1.54–2.41 6.7 10–9
Age-, sex- and stage-adjustedw
ISS-adjusted
UCSF (n¼ 140) 4.06 2.04–8.05 6.3 10–5
Mayo (n¼ 221) 2.41 1.51–3.83 2.2 10–4
Replicationz (n¼ 513) 1.70 1.19–2.44 0.004
Salmon–Durie-adjusted
UCSF (n¼ 256) 2.81 1.73–4.57 3.2 10–5
Mayo (n¼ 184) 2.75 1.68–4.49 5.3 10–5
Replicationz (n¼625) 1.46 1.04–2.05 0.029
CI, confidence interval; HR, hazard ratio; GWAS, genome-wide association study; PCA, principal
components analysis; IMMEnSE, International Multiple Myeloma rESEarch; MM, multiple
myeloma; UCSF, University of California San Francisco.
*P values are calculated from proportional hazards models.
wThe UCSF and Mayo Clinic study results are also adjusted with PCA. The IMMENSE data are
not owing to the lack of availability of GWAS data.
zThe IMMEnSE results are from a meta-analysis of the individual regions (see Supplementary
Table 3).
Table 3 | Effect of SNP by initial treatment among patients in
the UCSF cohort.
HR* 95% CI P valuew
Mayo Clinic
Old treatmentsz N¼ 136, 102 deaths
RS72773978 1.90 0.98–3.83 0.057
New treatmentsy N¼ 93, 64 deaths
RS72773978 2.71 1.56–4.70 0.00045
Entire sample adjusted for treatment, N¼ 229, 166 deaths
RS72773978 2.18 1.43–3.32 0.00028
UCSF
Old treatmentsz N¼ 124, 80 deaths
RS72773978 3.37 1.76–6.50 0.00026
New treatmentsy N¼ 208, 33 deaths
RS72773978 3.62 1.73–7.56 0.0006
Entire sample adjusted for treatment
RS72773978 3.35 2.07–5.41 8.2 10 7
CI, confidence interval; HR, hazard ratio; GWAS, genome-wide association study; SNP,
single-nucleotide polymorphism; UCSF, University of California San Francisco.
*All models are adjusted for age, gender and principal components 1–10.
wP values are calculated from proportional hazards models.
zRegimens including vincristine/adriamycin/dexamethasone or melphalan/prednisone.
yTreatments containing at least one of the following agents: thalidomide, botezomib or
lenalidomide.
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associated with mortality. The SNPs were in the region of the
FOPNL gene and a subset of the SNPs were associated with
FOPNL expression levels, with the minor allele predicting higher
expression22. We also found that FOPNL expression was
associated with poorer survival using data from a previous
study13. Thus, our results strongly suggest that FOPNL is a gene
involved in myeloma progression.
FOPNL is known to be associated with centrosome
function23,24. Centrosome amplification is common in MM and
is associated with poor prognosis25,26. Furthermore, inhibition of
centrosomal clustering may be effective in treatment of MM27,28.
We found that germline variation that affects a gene involved in
centrosomal function may also contribute to disease progression.
Furthermore, we found an association between FOPNL
expression and centrosome index in three data sets of gene
expression from myeloma samples. However, our results
implicating FOPNL as the causal gene at this locus rely on the
synthesis of several data sets. We were not able to directly
correlate the SNPs with gene expression, centrosome index and
survival in the same data set. It is possible that another gene/s at
this locus may be responsible for the effect we observe, or that the
effect is mediated by FOPNL, but that it is not through a
mechanism related to centrosome amplification. Additional
studies of this gene and centrosomal function will help to
further define the mechanism underlying the association that we
identified.
Our results imply that germline genetic variation is associated
with survival among patients with MM. Other GWAS have
identified loci that affect survival in other cancer types15–18,20. At
least one of the known loci for MM susceptibility is associated
with the risk for a particular subtype of MM4, which may also
have an effect on prognosis.
MM is a heterogeneous disease with substantial variation in
prognosis among different patients. Identifying patients who are
at higher risk of progression may be of importance in treating
these patients more aggressively earlier in their disease. Our
results identify the FOPNL genotype as a predictor of survival,
and we found that the association remains significant after
adjustment for stage at diagnosis. However, the effect size we
observed in the replication cohorts was substantially attenuated
compared with the effect size in the discovery cohorts. This
difference is most likely because of ‘winner’s curse’—a tendency
for the initial study to overestimate the true effect size29. Thus,
the replication cohorts in our study are more likely to represent
the true effect size in future studies.
Our study has several important limitations. We could not
examine the association between SNPs and MM survival by
cytogenetic abnormalities since the majority of our patients were
diagnosed before the common use of cytogenetic and fluorescent
in situ hybridization analyses in clinical practice. Therefore, it will
be important to examine the utility of this genotype in the setting
of cytogenetic and fluorescent in situ hybridization analyses and
gene expression signatures. Furthermore, we could not adjust for
gene expression patterns, which are also known to be associated
with survival.
We found no difference between patients who were initially
treated with modern versus older therapies. However, our ability
to analyse the SNP using different therapies was limited to the
UCSF data set and we had inadequate power to detect
interactions between the SNPs and particular drugs. Furthermore,
we only adjusted for the association between initial treatment
and survival, and it is likely that many of the patients who
were initially treated with older regimens received newer
regimens if they survived to the era when these became available.
It is possible that the effect that we saw is modified by one
regimen or by one class of medications. Additional studies should
be conducted in the context of clinical trials or other cohorts
where treatment regimens are more uniform to investigate
whether the effect of the locus we identified is modified by
particular treatments.
In summary, we found a strong association between a locus on
chromosome 16p and MM survival that is likely due to an effect
on expression of the FOPNL gene. The SNPs we identified may
become important clinical predictors of outcome among MM
patients.
Methods
Participants. UCSF study: The UCSF Institutional Review Board (IRB) approved
ascertainment of cases and use of existing biospecimens for genetic analysis. All
participants gave informed consent. The study included 370 patients treated for
MM at UCSF between 1989 and 2010. We excluded 10 samples because of
insufficient clinical data. We also excluded 42 participants whose blood was
collected Z2 years after diagnosis from the survival analysis because of the
potential bias towards long-term survivors among these participants. The median
delay between diagnosis and ascertainment among the 42 participants excluded
was 2.9 years (interquartile range 2.4–4.7 years). The median delay among the
participants included was 7.6 months (interquartile range 5.7–8.9 months).
We used white blood cells harvested after mobilization of stem cells with
granulocyte colony-stimulating factor as a source of DNA. Mobilization of stem
cells is performed before HDC followed by autologous stem cell transplantation.
The patient receives granulocyte colony-stimulating factor and then undergoes
harvesting of peripheral white blood cells via apheresis several days later30,31.
Bone marrow stem cell fraction is monitored via CD34 antibody, and apheresis is
continued until an adequate number of CD34þ cells have been collected for stem
cell rescue. The cells are then stored in liquid nitrogen.
We ascertained the date of death using chart reviews and death registry data.
Survival time was determined as the date of diagnosis until date of death or last
clinic visit for patients who were not known to have died. Clinical stage and initial
chemotherapy regimen was determined by chart review. For analysis of treatment,
we dichotomized treatments into either newer regimens (including an Imid
and/or proteasome inhibitor) or older regimens (including neither an Imid nor
proteasome inhibitor). Nearly all of the participants in the UCSF study (497%)
received HDC with stem cell rescue (autologous bone marrow transplant).
Mayo Clinic study: Ascertainment of MM cases and genotyping was approved
by the Mayo Clinic IRB. The study included incident MM cases seen in the regional
practice between 1998 and 2007 and recruited within 6 months of initial diagnosis.
Nearly all participants (96%) were recruited within 1 month of diagnosis and, the
remainder were recruited between 1 and 5.5 months after diagnosis. Eligible cases
provided consent and a blood sample for research studies of MM. A total of 243
MM cases were used for analyses. DNA was extracted from stored peripheral blood
samples. We ascertained date of death and calculated survival time as described for
the UCSF study. The clinical stage was determined by chart review. Clinical data on
survival could be ascertained on 239 patients. Initial chemotherapy regimen and
use of HDC was determined by chart review. For analysis of treatment, we
dichotomized treatments into either newer regimens (including an Imid and/or
proteasome inhibitor) or older regimens (including neither an Imid nor
proteasome Inhibitor). Approximately 56% of participants were treated with
autologous stem cell transplant.
IMMEnSE study: The IMMEnSE consortium is a case–control study recruited
from seven different European and North American countries32. MM cases are
defined by a confirmed diagnosis of MM, according to the International Myeloma
Working Group criteria33. For each patient, demographic and clinical parameters
at diagnosis and survival were collected by the responsible clinicians in each of the
IMMEnSE centres. The data collected are standardized in a central database kept at
the German Cancer Research Center (DKFZ, Heidelberg, Germany). For each
subject, a sample of peripheral blood or extracted DNA has been collected and sent
to DKFZ. A total of 772 MM cases with survival information available in the
IMMEnSE consortium were included in this study.
Utah study: Sampling and genetic analysis was approved by the University of
Utah IRB. The study included prevalent MM cases in the state of Utah, ascertained
up to 2012. Eligible cases provided consent and a blood or saliva sample from
which DNA was extracted. Date of diagnosis was confirmed from chart review and
Utah Cancer Registry data. Date of death was confirmed from chart review and
death registry data. Survival time was determined as the date of diagnosis until the
date of death, last contact with the study or last known event in Utah (determined
from statewide vital records, driver’s license renewals and voter registrations in the
Utah Population Database) for patients who were not known to have died. A total
of 318 MM cases with DNA and survival information were available for this study.
GWAS genotyping and imputation. All SNP positions were annotated using the
Genome Reference Consortium GRCh37 (Hg19) version of the human genome.
UCSF: A pilot study of 81 MM samples used an Illumina 660 array genotyped at
the UCSF Genomics Core Facility. In a second phase, we genotyped 289 MM
samples using an Illumina Omni5 array at Expression Analysis (Durham, NC).
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Of the 370 participants in the GWAS, 52 participants were excluded from the
survival analysis as noted above because of either insufficient clinical data (N¼ 10)
or because of 42 year time difference between diagnosis and ascertainment
(N¼ 42). Of the remaining 318 samples we dropped 12 since they did not pass
quality control for genotyping. Eleven were dropped because of high missing
genotype values (45% missing genotypes per sample) and one sample was
dropped because of potential contamination, leaving 306 patients. We dropped
SNPs that had 45% missing values or were monomorphic. Imputation was
performed using IMPUTE2 (ref. 34; https://mathgen.stats.ox.ac.uk/impute/
impute_v2.html#home) with all samples from 1000 Genomes data set (Version 2,
May 2011 release35) as a reference. Imputed SNPs with Informationo0.5 or
MAFo0.025 were excluded, leaving 8,036,255 SNPs for analysis.
Mayo Clinic: Cases were genotyped using the Affymetrix 6.0 array.
Monomorphic SNPs and those with a call rate o95% were excluded, leaving
786,950 observed SNPs. Four samples with call rates o95% and one sample with
non-European ancestry according to principal components analysis were excluded,
leaving 243 MM cases and 239 with follow-up past date of diagnosis. Imputation
was performed with BEAGLE36 (http://faculty.washington.edu/browning/beagle/
beagle.html), using all samples from version 2 of the 1,000 Genomes data
(May 2011 release) as reference. Imputed SNPs with an r2o0.3 or MAFo0.025
were excluded, leaving 7,276,170 SNPs for further analyses.
Replication genotyping. We selected two SNPs for replication in IMMEnSE
and Utah samples including one of the top two SNPs from the meta-analysis
(rs72773978) and a SNP in high linkage disequilibrium with the top SNP, encoding
a nonsynonymous amino-acid substitution in FOPNL (rs12598966). These SNPs
were typed using 50 exonuclease (TaqMan) assays (ABI) at the German Cancer
Research Center (DKFZ) in Heidelberg (IMMEnSE samples) and at the Genomics
Core at the University of Utah (Utah samples). Duplicates of 12% of the samples
were interspersed throughout the plates and concordance rate among duplicates
was 499.9%.
Statistical analysis. We performed genome-wide analyses for association with
survival using proportional hazards models in the UCSF and Mayo data sets
separately. We inferred genetic ancestry using principal components analysis
(PCA) in each cohort using SmartPCA37. Each SNP was entered into the model
under an assumption of log-additive increased risk, and adjusting for PC’s 1–3, age
and gender. Imputed SNPs were modelled using the probability of genotypes.
We tested the proportional hazards assumption for the top SNPs by calculating the
scaled Schoenfeld residuals and testing whether they are significantly associated
with time38.
We also performed a subset analysis of Caucasians only in the UCSF data set.
We identified Caucasians on the basis of genetic ancestry (see Supplementary
Fig. 2). Individuals who clustered with self-described Caucasians (PC140,
PC2o0) were included in this subset analysis (N¼ 229).
All analyses were performed in R. For graphing survival results, we used the
Kaplan–Meier estimates of the survival function and graphed the results using Stata
(Version 10). We graphed the association statistics for all SNPs near the top locus
using LocusZoom39.
We used Cox regression models adjusted for age and gender to test the
association between SNPs and survival in the IMMEnSE consortium and the Utah
cohort.
We performed a meta-analysis of the UCSF and Mayo Clinic results on a total
of 6,026,834 SNPs in common from both GWAS that met the allele frequency and
imputation quality thresholds. We also conducted a meta-analysis of data on two
top SNPs from seven centres within the IMMEnSE consortium and the Utah study
in our replication study. We calculated a fixed effects model for each SNP using
METAL40. We used Cochran’s Q statistic to test for heterogeneity.
To examine the association of SNPs and risk of MM, we compared the genotype
frequencies of cases versus ethnically matched controls from the UCSF (N¼ 298)
and the Mayo Clinic (N¼ 295) sites, respectively. We used logistic regression
models, adjusting for PC1–3 age and gender.
Expression quantitative trait locus (eQTL) analysis. We used the data set from
ref. 22 for eQTL analyses, which consists of 856 Caucasian individuals including
154 monozygotic twin pairs, 232 dizygotic twin pairs and 84 singletons. We
focused on expression in lymphocytes in this data set. We used GENEVAR21 to
query the top 145 SNPs from the GWAS and identified 6 SNPs, that were also in
the data set described in ref. 22. We queried GENEVAR for beta coefficients and P
values for associations between six SNPs and the genes within a 1-Mb window,
including FOPNL, MYH11, ABCC1, NDE1, KIAA0430, ABCC6, RRN3, NTAN1
KIAA0250 and KIAA0251.
Gene expression and centrosome index. We downloaded gene expression data
from refs 13,41,42 from the National Institutes of Health Gene Expression
Omnibus (accession number: GSE2658, GSE19784 and GSE26760, respectively).
Reference 13 consisted of gene expression data from 559 MM samples assayed on
Affymetrix U133 arrays; ref. 41 consisted of gene expression data from purified
CD138þ plasma cells of 320 newly diagnosed myeloma patients using Affymetrix
GeneChip U133 plus 2.0 arrays; ref. 42 consisted of 304 CD138-purified bone
marrow samples from patients with MM were analysed on Affymetrix U133 Plus
2.0 microarrays.
Gene expression and MM outcome: Of the samples in the Zhan et al.13 data set,
414 also had available clinical data and were included in the original publication
and, therefore, we used the data from these 414 samples in our analyses. We used
log-transformed probe intensity values as predictors of survival, entering these as
continuous variables into a proportional hazards model. We analysed each of the
two probes for FOPNL on the Affymetrix U133 array separately and also
considered the average of the two probes as a predictor of overall survival in the
proportional hazards model.
Analysis of potential SNP function: We used SIFT43 and Polyphen2 (ref. 44) to
determine the likelihood that a nonsynonymous amino-acid substitution has a
deleterious effect on protein function. We used FunciSNP45 to determine whether
any of the SNPs may affect gene expression, including any SNPs with R240.7 with
rs72773928. R2 values for linkage disequilibrium were calculated in European
ancestry samples from 1,000 genomes.
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Corrigendum: Genome-wide association study
identifies variants at 16p13 associated with survival
in multiple myeloma patients
Elad Ziv, Eric Dean, Donglei Hu, Alessandro Martino, Daniel Serie, Karen Curtin, Daniele Campa, Blake Aftab,
Paige Bracci, Gabriele Buda, Yi Zhao, Jennifer Caswell-Jin, Robert Diasio, Charles Dumontet, Marek Dudzin´ski,
Laura Fejerman, Alexandra Greenberg, Scott Huntsman, Krzysztof Jamroziak, Artur Jurczyszyn, Shaji Kumar,
Djordje Atanackovic, Martha Glenn, Lisa A. Cannon-Albright, Brandt Jones, Adam Lee, Herlander Marques,
Thomas Martin, Joaquin Martinez-Lopez, Vincent Rajkumar, Juan Sainz, Annette Juul Vangsted, Marzena Watek,
Jeffrey Wolf, Susan Slager, Nicola J. Camp, Federico Canzian & Celine Vachon
Nature Communications 6:7539 doi: 10.1038/ncomms8539 (2015); Published 22 Jul 2015; Updated 9 Dec 2015
In this Article, members of the UCSF cohort who had been alive for longer than two years were inadvertently included in the data
presented in Table 3. USCF/old treatments should have 109 patients with a hazard ratio of 3.35 and a P value of 0.00028 instead of the
124 patients with a hazard ratio of 3.37 and a P value of 0.00026. The USCF/new patients should have 187 patients with a hazard ratio
of 3.57 and a P value of 0.0007 instead of the 208 patients with a hazard ratio of 3.62 and a P value of 0.0006. Finally, in the table
legend, the first line should read ‘All models are adjusted for age, gender and principal components 1–3’. The exclusion of these
individuals does not change the conclusions of the study. The correct version of Table 3 appears below.
Table 3 | Effect of SNP by initial treatment among patients in the UCSF cohort.
HR* 95% CI P valuew
Mayo Clinic
Old treatmentsz N¼ 136, 102 deaths
RS72773978 1.90 0.98–3.83 0.057
New treatmentsy N¼93, 64 deaths
RS72773978 2.71 1.56–4.70 0.00045
Entire sample adjusted for treatment N¼ 229, 166 deaths
RS72773978 2.18 1.43–3.32 0.00028
UCSF
Old treatmentsz N¼ 109 60 deaths
RS72773978 3.35 1.74–6.44 0.00028
New treatmentsy N¼ 187, 30 deaths
RS72773978 3.57 1.71–7.43 0.0007
Entire sample adjusted for treatment N¼ 296, 90 deaths
RS72773978 3.35 2.07–5.41 8.2 10 7
*All models are adjusted for age, gender and principal components 1-3.
wP values are calculated from proportional hazards models.
yTreatments containing at least one of the following agents: thalidomide, botezomib or lenalidomide.
zRegimens including vincristine/adriamycin/dexamethasone or melphalan/prednisone.
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